Skip to content
Home/Companies/MedTech/SAGA Dx

SAGA Dx

MedTech·Sweden·Exited 2026·Held 5yr
Entry
2021
Hold
5yr
Exit
2026

Who owns SAGA Dx?

SAGA Dx is a Swedish MedTech company, now owned by Foundation Medicine, which acquired it in 2026 from Segulah Medical Acceleration.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Segulah Medical Acceleration
Investor
Segulah Medical Acceleration
Segulah Medical Acceleration · 2021 · Life Sciences VC

Key facts

HQSweden
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
Foundation Medicine (Roche)
Exit Year
2026

More from Segulah Medical Acceleration

Other portfolio companies in the same fund.

Basic Genomics
Active
BiotechSweden· 2025
Protembis
Protembis
Active
MedTechGermany· 2024
Collective Minds Radiology
Active
HealthTechSweden· 2023
Senzime
Active
MedTechSweden· 2023
Navinci Diagnostics
Active
BiotechSweden· 2022
CytaCoat
Active
MedTechSweden· 2021

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns SAGA Dx?

SAGA Dx is now owned by Foundation Medicine, which acquired it in 2026 from Segulah Medical Acceleration.

When did Foundation Medicine acquire SAGA Dx?

Foundation Medicine acquired SAGA Dx in 2026, buying from Segulah Medical Acceleration.

Who did SAGA Dx sell to?

Segulah Medical Acceleration sold SAGA Dx to Foundation Medicine in 2026 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue